789 |
NOBORI -Clinical Studies Updates |
Gian Battista Danzi |
Jul. 22. 09 |
788 |
Stentdesign Comparison and Clinical Perspectives |
Yutaka Hikichi |
Jul. 22. 09 |
787 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
Jul. 22. 09 |
786 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
Jul. 22. 09 |
785 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
784 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
783 |
Strategic Approaches to Obtain Better and Earlier CV Outcome |
Weon Kim |
Jul. 22. 09 |
782 |
The Impact of Diabetes in the DES Long-Term Outcome |
Seung-Jung Park |
Jul. 22. 09 |
781 |
Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years |
Martin Bert Leon |
Jul. 22. 09 |
780 |
Real World Experiences of 2nd Generation DES |
Ian T. Meredith |
Jul. 22. 09 |